Projects per year
Personal profile
Education/Academic qualification
Master
Fingerprint
Dive into the research topics where Elisa Ardizzoni is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
THREE-G: The causes and consequences of historical contingencies in the evolution of extensively drug-resistant Mycobacterium tuberculosis
Gagneux, S., Ardizzoni, E., Rigouts, L. & de Jong, B.
1/01/25 → 31/12/28
Project: Research Project
-
TB/NTM Cluster: TB/NTM Onderzoekscluster
Sengstake, S., Rigouts, L., Tzfadia, O., Ardizzoni, E., Lynen, L., Decroo, T., Hasker, E., Van Rie, A., Lynen, L., Hasker, E. & de Jong, B.
1/01/22 → 31/12/26
Project: Research Project
-
MSF Routine: MSF Routine Services
de Jong, B., Ardizzoni, E. & de Jong, B.
1/03/20 → 28/02/26
Project: Service
-
EndTB O5: EndTB-Q Output 5 testing new regimens to treat MDR-TB resistant to fluoroquinilones
Ardizzoni, E., de Jong, B. & de Jong, B.
1/07/20 → 30/06/25
Project: Research Project
-
Effectiveness and tolerability of a short regimen for drug resistant tuberculosis treatment in Kandahar Province, Afghanistan, Uncontrolled Clinical Study
de Jong, B., Ardizzoni, E. & Janssens, N.
1/09/19 → 30/04/22
Project: Research Project
Research output
-
Bedaquiline, delamanid, linezolid, and clofazimine for rifampicin-resistant and fluoroquinolone-resistant tuberculosis (endTB-Q): an open-label, multicentre, stratified, non-inferiority, randomised, controlled, phase 3 trial
endTB-Q Clinical Trial Team, 2025, In: Lancet Respiratory Medicine. 13, 9, p. 809-820 12 p.Research output: Contribution to journal › A1: Web of Science-article › peer-review
Open Access -
Direct thin-layer agar for bedaquiline-susceptibility testing of Mycobacterium tuberculosis at BSL2 level yields high accuracy in 15 days from sputum processing
Cuella-Martin, I., Runyambo, D., De Bock, S., Diels, M., Niyompano, H., Hakizayezu, F., Keysers, J., De Rijk, WB., Habimana, YM., Gahamanyi, N., Ardizzoni, E., Muvunyi, CM., de Jong, BC., Ngabonziza, JCS. & Rigouts, L., 2025, In: Journal of Clinical Microbiology. 63, 4, 11 p.Research output: Contribution to journal › A1: Web of Science-article › peer-review
Open Access -
Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia
Ardizzoni, E., Mulders, W., Fuertes, MD., Hayrapetyan, A., Mirzoyan, A., Faqirzai, J., Khachatryan, N., Oganezova, I., Varaine, F., Bastard, M., Graulus, P., Meehan, CJ., Rigouts, L., de Jong, BC., Decroo, T., Hewison, C. & Van Rie, A., 2025, In: Antimicrobial Agents and Chemotherapy. 69, 5, 13 p.Research output: Contribution to journal › A1: Web of Science-article › peer-review
Open Access -
Reduced critical concentration might not have improved MGIT-based DST’s sensitivity to rifampicin
Rupasinghe, P., de Rijk, W. B., Calderon, R., Rigouts, L., Guglielmetti, L., Mitnick, C. D., de Jong, B., Rusheed, N., Ardizzoni, E., Ha, D. T., Hang, P. T., Bulane, A., Chingisova, L., Hirani, N., Asif, S., Azka, A., Barreda, N., Parveen, S. & Zubair, M., 2024, In: Antimicrobial Agents and Chemotherapy. 68, 5, e01701-23.Research output: Contribution to journal › Letter › peer-review
Open Access -
Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial
Rupasinghe, P., Patil, S. B., Tamirat, M., Khazhidinov, K., Ardizzoni, E., Atger, M., Austin, A., Baudin, E., Bekhit, M., Bektasov, S., Berikova, E., Bonnet, M., Caboclo, R., Chaudhry, M., Chavan, V., Cloez, S., Coit, J. M., Coutisson, S., Dakenova, Z., de Jong, B., & 33 others, 2023, In: Trials. 24, 1, 14 p., 773.Research output: Contribution to journal › A1: Web of Science-article › peer-review
Open Access